Table 4 Results of logistic regression, effect of a shorter duration of action (<4 months) of intravitreal dexamethasone implantation in DME patients.
Category | n(%) | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|
OR (95%CI) | p | OR (95%CI) | p | ||||
Sex | Female | 31 (65.96%) | Reference | ||||
Male | 16 (34.04) | 2.40 (0.61,12.11) | 0.238 | ||||
Age (years) | ≤57 | 32 (68.09%) | Reference | ||||
>57 | 15 (31.91%) | 0.99 (0.28, 3.42) | 0.989 | ||||
HbA1c | ≤7 | 15 (31.91%) | Reference | ||||
>7 | 32 (68.09%) | 0.69 (0.16, 2.59) | 0.598 | ||||
DMR stage | NPDR | 19 (40.43%) | Reference | ||||
PDR | 28 (59.57%) | 0.41 (0.10, 1.49) | 0.194 | ||||
CST (μm) | ≤400 | 15 (31.91%) | Reference | ||||
>400 | 32 (68.09%) | 2.62 (0.72, 9.82) | 0.143 | ||||
EZ disruption | (−) | 20 (42.55%) | Reference | ||||
(+) | 27 (57.45%) | 1.28 (0.37, 4.45) | 0.696 | ||||
Number of HF | ≤10 | 27 (57.45%) | Reference | Reference | |||
>10 | 20 (42.55%) | 20.46 (3.46, 394.23) | 0.006 | 17.17 (2.80, 344.84) | 0.010 | ||
Retinal morphology | type | DRT | 24 (51.06%) | Reference | |||
CME | 23 (48.94%) | 1.70 (0.50, 6.16) | 0.403 | ||||
SRD | (−) | 36 (76.60%) | Reference | ||||
(+) | 11 (23.40%) | 0.46(0.11, 1.92) | 0.277 | ||||
IL-1β (pg/mL) | ≤0.98 | 24 (51.06%) | Reference | ||||
>0.98 | 23 (48.94%) | 0.77 (0.22, 2.65) | 0.680 | ||||
IL-8 (pg/mL) | ≤18.18 | 24 (51.06%) | Reference | Reference | |||
>18.18 | 23 (48.94%) | 4.02 (1.11, 17.15) | 0.043 | 2.82 (0.64, 13.85) | 0.177 | ||
IL-10 (pg/mL) | <1.60 | 36 (76.60%) | Reference | ||||
≥1.60 | 11 (23.40%) | 0.77 (0.19, 3.44) | 0.718 | ||||
IL-17 (pg/mL) | ≤1.80 | 24 (51.06%) | Reference | ||||
>1.80 | 23 (48.94%) | 0.52 (0.14, 1.78) | 0.302 | ||||
VEGF (pg/mL) | ≤70.44 | 24 (51.06%) | Reference | ||||
>70.44 | 23 (48.94%) | 1.70 (0.50, 6.16) | 0.403 | ||||
PlGF (pg/mL) | ≤2.14 | 24 (51.06%) | Reference | ||||
>2.14 | 23 (48.94%) | 1.70 (0.50, 6.16) | 0.403 | ||||
